Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deep China Price Cuts Reveal Complex Considerations

This article was originally published in PharmAsia News

Executive Summary

Offering deep price discounts in exchange for inclusion in reimbursement lists is never easy, given companies' need to balance expected benefits in volume gains with their international pricing systems and commercial pressures. But in China the underlying considerations are even more complex, as shown by the latest round of national price reductions for selected drugs.

You may also be interested in...



China Vs. Cancer: Seven Companies Given Price Cuts, Roche Gets New Approval

Cancer drug prices again on the chopping board in China, including for some products already affected, and more are coming.

Set, Ready, Walk: Gilead Unveils Sovaldi Strategy In China

Rapid regulatory changes in China are expected to trigger a flurry of new drug launch activities. As Q3 earnings season plays out, Gilead COO Kevin Young talks about doing ‘the right thing’ while rolling out products like the high-priced Sovaldi in China's private-pay market.

Sweeping China Policy Reforms Seen Bolstering Domestic Generics

Off-patent original drugs in China are set to face unprecedented competition as the country drives up policy support for high-quality, bioequivalent domestic generics, and outlines other sweeping moves covering pricing and compulsory licenses.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC089517

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel